NASDAQ$PACB

Pacific Biosciences of California Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Pacific Biosciences reported mixed Q1 2023 results, exceeding revenue expectations but falling short on earnings per share.

Pacific Biosciences' Q1 2023 revenue reached $38.7 million, surpassing expectations, but the company experienced a net loss, resulting in negative EPS. Instrument revenue grew, while consumables revenue declined slightly. The company highlighted progress in its product development and market expansion efforts.

  • Revenue reached $38.7 million, exceeding expectations.
  • Instrument revenue increased year-over-year.
  • Consumables revenue experienced a slight decline compared to the previous year.
  • The company is making progress on product development and market expansion.

Headline financials

Total Revenue

$38.9M

Previous: $33.2M+17.3%
EPS (adj)

-$0.31

Previous: -$0.37+16.2%
Capital Expenditures

-$3.72M

Previous: -$3.64M-2.3%
Free Cash Flow

-$91.7M

Previous: -$85.1M-7.8%
Net Income

-$88M

Previous: -$81.5M-8.0%
Operating Income

-$91.3M

Previous: -$77.5M-17.7%
Gross Profit

$9.76M

Previous: $14.2M-31.0%
Cash & Equivalents

$354M

Previous: $429M-17.4%
Total Assets

$1.9B

Previous: $1.94B-2.1%
Stock-Based Comp

$18M

Previous: $22.7M-20.9%

Revenue & EPS history

Pacific Biosciences · Revenue · Quarterly

$38.9M

Q1 2023+17.3%vs Q1 2022
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Revenue by segment

Pacific Biosciences · $38.7M total across 3 segments · Q1 2023

  • Instrument Revenue
    $21.7M+24.7%
  • Consumables Revenue
    $15.4M+136.9%
  • Service & Other Revenue
    $1.6M-82.0%

Forward guidance

PacBio anticipates revenue between $165 million and $175 million for the full year 2023.

Tailwinds

  • Revenue between $165 million and $175 million for the full year 2023.
  • Continued growth in instrument revenue expected.
  • Anticipated increase in consumables revenue as installed base expands.
  • Focus on expanding market reach and customer base.
  • Advancements in product development to drive future growth.

Headwinds

  • Uncertainties in the macroeconomic environment could impact sales.
  • Potential delays in product development timelines.
  • Increased competition in the long-read sequencing market.
  • Fluctuations in currency exchange rates may affect international revenue.
  • Dependence on key suppliers for critical components.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+1.6%

Avg return

Earnings day

+2.4%

Avg return

5 days after

+4.1%

Avg return

30 days after

47%

29 / 62 earnings

Positive

+69.9%

Q3 2018

Best reaction

-27.2%

Q3 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-14.5%-23.0%-12.7%
Q4 2025-7.1%-11.4%-27.7%
Q3 2025-1.1%-2.2%+34.3%
Q1 2025-8.4%-8.3%-5.0%
Q4 2024+25.0%+19.6%-17.6%
Q3 2024-13.2%-16.6%-23.4%
Q2 2024+4.4%-10.6%-1.2%
Q1 2024+5.4%+32.7%+19.6%
Q4 2023+9.7%-18.6%-41.7%
Q3 2023+20.9%+15.2%+48.7%
Q2 2023-0.7%-3.7%-13.3%
Q1 2023-2.8%-0.5%+13.6%
Q4 2022+5.1%-17.6%-25.2%
Q3 2022+2.1%+11.8%+31.9%
Q2 2022+11.4%+27.4%-10.3%
Q1 2022-4.5%+2.9%-7.1%
Q4 2021+8.2%+4.5%-0.5%
Q3 2021+6.6%+5.3%-22.1%
Q2 2021+5.5%+4.1%+0.2%
Q1 2021-0.2%-3.4%+4.7%
Q4 2020+29.4%+27.3%-14.3%
Q3 2020+16.1%+18.2%+62.7%
Q2 2020-3.1%+1.0%+66.5%
Q1 2020+9.4%+11.6%+26.7%
Q4 2019-4.1%-12.3%-16.3%
Q3 2019-2.8%-4.8%+3.5%
Q2 2019+3.5%+5.6%+4.1%
Q1 2019-0.3%-1.3%-9.6%
Q4 2018-1.5%-0.8%+1.5%
Q3 2018+69.9%+71.2%+75.7%
Q2 2018+0.5%+4.7%+31.7%
Q1 2018-8.7%-6.9%+0.8%
Q4 2017-4.9%-8.5%-16.2%
Q3 2017-27.2%-33.9%-27.2%
Q2 2017+13.7%+38.8%+57.1%
Q1 2017-19.4%-20.3%-27.2%
Q4 2016-1.2%-1.7%+6.2%
Q3 2016-20.4%-12.7%-17.4%
Q2 2016+14.6%+10.3%+6.8%
Q1 2016+18.2%
Q4 2015-24.0%
Q3 2015+9.7%
Q2 2015-17.2%
Q1 2015-0.5%
Q4 2014-16.4%
Q3 2014+11.8%
Q2 2014+2.6%
Q1 2014-5.6%
Q4 2013+2.2%
Q3 2013+0.0%
Q2 2013+5.7%
Q1 2013-0.4%
Q4 2012+0.0%
Q3 2012-5.4%
Q2 2012+2.9%
Q1 2012+0.0%
Q4 2011-12.7%
Q3 2011-7.8%
Q2 2011+8.9%
Q1 2011-1.3%
Q4 2010+2.7%
Q3 2010+9.2%
Q2 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro